vTv Therapeutics Inc.
For the period ended Sep 30, 2026. Filed Nov 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 5, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Rule 10b5-1 Trading Plans
During the third fiscal quarter ended September 30, 2026, except as provided below, none of our directors or executive officers adopted orterminated any contract, instruction or written plan for the purchase or sale of our securities to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any “non-Rule 10b5-1 trading arrangement.”
On September 3, 2026, Michael Tung, Executive Vice President and Chief Financial Officer, adopted a written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) for the potential sale of the Company’s Class A common stock. The arrangement ends on December 31, 2027, or earlier if all shares subject to the arrangement are sold and covers the potential sale of up to 36,553 shares of common stock.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.